Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213963 | 0.89 | CYP1A2 (0.62) | CYP1A2SMN1; SMN2KDM4ENPC1CYP2C9 | |
| SCHEMBL61315 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL28161848 | 0.87 | — | — | |
| Hydroxyl Radical SCHEMBL28261927 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL27929151 | 0.87 | — | — | |
| SCHEMBL29452963 | 0.87 | — | — | |
| Potassium SCHEMBL30601771 | 0.87 | — | — | |
| Water SCHEMBL28135826 | 0.84 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2KDM4ENPC1CYP2C9 | |
| Cyanide SCHEMBL28083497 | 0.82 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2KDM4ENPC1CYP2C9 | |
| Formaldehyde SCHEMBL28333125 | 0.82 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2KDM4ENPC1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287459-B1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| EP-3287459-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | HDAC5, HDAC2, HDAC8 | CYP1A2 2230/4885SMN1; SMN2 4515/4885KDM4E 428/4885 |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | HDAC5, HDAC2, HDAC8 | CYP1A2 2230/4885SMN1; SMN2 4515/4885KDM4E 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.